2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. trimmed its stake in 2seventy bio, Inc. (NASDAQ:TSVT) by 7.9% during the third quarter, HoldingsChannel.com reports. The fund owned 413,599 shares of the company’s stock after selling 35,679 shares during the period. Charles Schwab Investment Management Inc.’s holdings in 2seventy bio were worth $1,952,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Marshall Wace LLP boosted its position in shares of 2seventy bio by 50.4% in the 2nd quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock valued at $2,568,000 after purchasing an additional 223,408 shares during the period. Venator Management LLC boosted its holdings in shares of 2seventy bio by 49.2% in the second quarter. Venator Management LLC now owns 485,000 shares of the company’s stock worth $1,867,000 after buying an additional 160,000 shares during the period. Stonepine Capital Management LLC acquired a new position in shares of 2seventy bio in the second quarter worth about $385,000. Susquehanna Fundamental Investments LLC increased its position in shares of 2seventy bio by 39.1% in the second quarter. Susquehanna Fundamental Investments LLC now owns 192,319 shares of the company’s stock worth $740,000 after acquiring an additional 54,076 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of 2seventy bio during the third quarter valued at approximately $80,000. 93.90% of the stock is owned by institutional investors and hedge funds.

2seventy bio Stock Performance

Shares of NASDAQ:TSVT opened at $3.26 on Tuesday. 2seventy bio, Inc. has a 52 week low of $2.89 and a 52 week high of $6.40. The company has a market cap of $168.18 million, a PE ratio of -1.75 and a beta of 1.69. The firm has a 50 day simple moving average of $4.25 and a 200 day simple moving average of $4.35.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.